This training course is all about differential diagnosis and therapy of hypertrophic cardiomyopathies (HCM). First, the previously known etiologies and their respective frequencies are highlighted. The very large group of unknown etiologies (almost 30%) suggests that many patients with rarer diseases have simply not (yet) been diagnosed there.
This webinar is all about differential diagnosis and therapy of hypertrophic cardiomyopathies (HCM). First, the previously known etiologies and their respective frequencies are highlighted, whereby the very large group of unknown etiologies (almost 30%) suggests that many patients with rarer diseases have simply not (yet) been diagnosed there.Prof. Patten uses three case histories to show that comparable cardiac symptoms and relatively nonspecific echo findings can be due to completely different diagnoses. Examples of common sarcoma mutations, ATTR amyloidosis, and Fabry disease are outlined, with the expert addressing specifics of history, physical examination, ECG, and laboratory values in each case. The possibilities of genetic testing are also presented, since HCM is often hereditary.Since effective therapeutics are now available for many diseases, a close medical look is worthwhile today, says Prof. Patten. Using two case studies, she vividly presents the path from the first sign of disease to successful treatment – taking into account family history features, seminal factors in enzymology and imaging, and using guideline-based algorithms.
PD Dr. Peter Nordbeck will then focus his presentation on the lysosomal storage disease Fabry disease. He comprehensively addresses the prevalence, pathophysiology, and symptomatology of this rare but underdiagnosed disorder. In addition to the influence on the skin, the kidneys and the peripheral as well as central nervous system, the heart specialist describes in particular the cardiac effects of this X-linked inherited disease. Here he names important red flags, describes typical courses, explains the steps up to diagnosis and then devotes himself to the therapeutic options available today. Fabry disease is a chronic progressive systemic disease that leads to multiple organ damage if left untreated. Early detection and therapy is also essential in this case. And so, in conclusion, Dr. Nordbeck emphasizes how important it is to always clarify an unclear left ventricular hypertrophy (LVH) in a well-founded manner.
After the video training, click on START TEST to go to the online training.
Speakers:
| Prof. Dr. med. Monika Patten University Heart and Vascular Center Hamburg (D) Cardiology clinic |
PD Peter Nordbeck, MD Senior physician University Hospital Würzburg (D) |
 |
 |
| Prof. Patten uses three case histories to show that comparable cardiac symptoms and relatively nonspecific echo findings can be due to completely different diagnoses. | PD Dr. Peter Nordbeck will then focus his presentation on the lysosomal storage disease Fabry disease. |
Read this advanced training in print; published in CARDIOVASC 4/2020.
